[ad_1]
Insulet Company (NASDAQ Stock Code:PODD) (Insulet or our company), the world’s leading Tubeless insulin pump Omnipod technology® The brand’s product today announced the promising results of its latest Omnipod 5 automatic insulin delivery system (Omnipod 5) in a key trial in young children. Omnipod 5 is the world’s first tubeless, wearable automatic insulin delivery (AID) system. It continuously adjusts insulin delivery based on blood glucose levels and trends, significantly improving the range and time of children with type 1 diabetes from 2 to 5.9 years of age. HbA1c. These key research data from the preschool age group have been announced at the 81st Virtual Science Conference of the American Diabetes Association (ADA).
“Controlling type 1 diabetes in very young children is particularly challenging because of their unpredictable eating patterns, unstable physical activity, and increased fear of caregivers’ hypoglycemia, because these patients are often unable to self-treat or express them in words Symptoms,” said Dr. Trang Ly MBBS, FRACP, PhD, Senior Vice President and Medical Director of Insulet. “Omnipod 5 has great potential in improving the results and ease of use for our youngest patients, and we are happy to share these key trial results.”
Overview of key preschool research in Omnipod 5
Insulet recruited 80 preschool children from 10 locations in the United States to participate in the study. Participants were between 2 and 5.9 years of age with HbA1c below 10.0%. After 14 days of standard therapy, Omnipod was used at home for 5 3 months, including pump therapy or multiple daily injections (MDI). Throughout the study, the children’s diet and exercise were not restricted.
Studies have shown that HbA1c has decreased overall from an average of 7.4% to 6.9%, and the time within the range has increased significantly (70-180 mg/dL), from an average of 57.2% to 68.1%, or an additional 2.6 hours per day. The median time to hypoglycemia (<70 mg/dL) overall decreased from 2.2% to 1.9%.
In addition, according to the Pittsburgh Sleep Quality Index (PSQI) assessment, the parents and caregivers of study participants reported improvements in sleep quality1, Is considered to be the gold standard questionnaire for measuring subjective sleep quality. Parents and caregivers reporting “very good” or “fairly good” sleep increased from 65% at baseline to 90% at the end of the study.
“These results are impressive, not only for our youngest patients, but also for their families,” said Dr. Jennifer Sherr, principal investigator and associate professor at Yale University School of Medicine. “Diabetes is a team sport-all family members are affected and usually have a profound effect. Sleep quality is often poor when caregivers work to ensure safety, and the fatigue that comes with it can affect family dynamics. These results indicate that Omnipod 5 can have a positive impact on the entire family.”
It is also worth noting that 100% of preschool key trial participants choose to continue…
The full story on Benzinga.com
[ad_2]
Source link
